View Item 

Show simple item record

Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials

dc.contributor.authorFitzcharles, Mary‐ann
dc.contributor.authorSte‐marie, Peter A.
dc.contributor.authorHäuser, Winfried
dc.contributor.authorClauw, Daniel J.
dc.contributor.authorJamal, Shahin
dc.contributor.authorKarsh, Jacob
dc.contributor.authorLandry, Tara
dc.contributor.authorLeclercq, Sharon
dc.contributor.authorMcdougall, Jason J.
dc.contributor.authorShir, Yoram
dc.contributor.authorShojania, Kam
dc.contributor.authorWalsh, Zach
dc.date.accessioned2017-01-06T20:46:52Z
dc.date.available2017-07-10T14:31:42Zen
dc.date.issued2016-05
dc.identifier.citationFitzcharles, Mary‐ann ; Ste‐marie, Peter A. ; Häuser, Winfried ; Clauw, Daniel J.; Jamal, Shahin; Karsh, Jacob; Landry, Tara; Leclercq, Sharon; Mcdougall, Jason J.; Shir, Yoram; Shojania, Kam; Walsh, Zach (2016). "Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials." Arthritis Care & Research 68(5): 681-688.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/134861
dc.publisherWiley Periodicals, Inc.
dc.titleEfficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134861/1/acr22727_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134861/2/acr22727.pdf
dc.identifier.doi10.1002/acr.22727
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceFiz J, Duran M, Capella D, Carbonell J, Farre M. Cannabis use in patients with fibromyalgia: effect on symptoms relief and healthâ related quality of life. PLoS One 2011; 6: e18440.
dc.identifier.citedreferenceSwift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J 2005; 2: 18.
dc.identifier.citedreferenceWare MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract 2005; 59: 291 â 5.
dc.identifier.citedreferenceWalsh Z, Callaway R, Belleâ Isle L, Capler R, Kay R, Lucas P, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy 2013; 24: 511 â 6.
dc.identifier.citedreferenceWare MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic nonâ cancer pain: results of a prospective survey. Pain 2003; 102: 211 â 6.
dc.identifier.citedreferenceFitzcharles MA, McDougall J, Steâ Marie PA, Padjen I. Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? Arthritis Rheum 2012; 64: 2417 â 25.
dc.identifier.citedreferencePertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3353 â 63.
dc.identifier.citedreferencePertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147 Suppl 1: S163 â 71.
dc.identifier.citedreferenceRobson P. Abuse potential and psychoactive effects of deltaâ 9â tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011; 10: 675 â 85.
dc.identifier.citedreferenceElsohly MA, D Slade. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005; 78: 539 â 48.
dc.identifier.citedreferenceBooker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, et al. The fatty acid amide hydrolase (FAAH) inhibitor PFâ 3845 acts in the nervous system to reverse LPSâ induced tactile allodynia in mice. Br J Pharmacol 2012; 165: 2485 â 96.
dc.identifier.citedreferenceFitzcharles MA, Steâ Marie PA, Clauw DJ, Jamal S, Karsh J, LeClercq S, et al. Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints. BMC Musculoskelet Disord 2014; 15: 258.
dc.identifier.citedreferenceHiggins JP, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). 2011. URL: http://handbook.cochrane.org/.
dc.identifier.citedreferenceGuyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonsoâ Coello P, et al. GRADE guidelines: 4. Rating the quality of evidenceâ study limitations (risk of bias). J Clin Epidemiol 2011; 64: 407 â 15.
dc.identifier.citedreferenceNarang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008; 9: 254 â 64.
dc.identifier.citedreferenceSchley M, Legler A, Skopp G, Schmelz M, Konrad C, Rukwied R. Deltaâ 9â THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006; 22: 1269 â 76.
dc.identifier.citedreferenceHaroutiunian S, Rosen G, Shouval R, Davidson E. Openâ label, addâ on study of tetrahydrocannabinol for chronic nonmalignant pain. J Pain Palliat Care Pharmacother 2008; 22: 213 â 7.
dc.identifier.citedreferenceBlake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabisâ based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 50 â 2.
dc.identifier.citedreferenceHuggins JP, Smart TS, Langman S, Taylor L, Young T. An efficient randomised, placeboâ controlled clinical trial with the irreversible fatty acid amide hydrolaseâ 1 inhibitor PFâ 04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012; 153: 1837 â 46.
dc.identifier.citedreferenceSkrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9: 164 â 73.
dc.identifier.citedreferenceWare MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia and Analgesia 2010; 110: 604 â 10.
dc.identifier.citedreferenceBennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009; 36: 1304 â 11.
dc.identifier.citedreferenceLynch ME, F Campbell. Cannabinoids for treatment of chronic nonâ cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 2011; 72: 735 â 44.
dc.identifier.citedreferenceMartinâ Sanchez E, Furukawa TA, Taylor J, Martin JL. Systematic review and metaâ analysis of cannabis treatment for chronic pain. Pain Med 2009; 10: 1353 â 68.
dc.identifier.citedreferenceMurphy SL, Phillips K, Williams DA, Clauw DJ. The role of the central nervous system in osteoarthritis pain and implications for rehabilitation. Curr Rheumatol Rep 2012; 14: 576 â 82.
dc.identifier.citedreferenceKlein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225: 1 â 8.
dc.identifier.citedreferenceAggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag 2009; 5: 257 â 86.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr22727_am.pdf
Size:
454.0KB
Format:
PDF
View/Open
Name:
acr22727.pdf
Size:
236.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.